Inactivation of cadmium induced immunotoxicological alterations in rats by Tunisian montmorillonite clay.
Cadmium (Cd(2+)) is a heavy metal that is dispersed throughout the modern environment mainly as a result of pollution from a variety of sources. The aims of the current study were to investigate the efficacy of purified Tunisian montmorillonite clay (TMC) to adsorb Cd, to test the stability of the resulting complex under different conditions in vitro, and to utilize the rat bioassay as an in vivo model to evaluate the protective role of TMC against Cd-induced toxicity and immunodysfunction. In the in vitro study, three concentrations of TMC (0.5, 1.0 and 1.5 g/l aqueous solution) and three concentrations of CdCl(2) (25, 50 and 100 ppm) were tested. The results of the in vitro study showed that TMC had a high capacity of adsorbing Cd at different concentrations tested. The adsorption ranged from 95.7-100% of the available CdCl(2) in aqueous solutions. The complex TMC-Cd was stable at different pHs at 37 degrees C. The in vivo results indicated that treatment with CdCl(2) (2.5 mg/kg BW) for 2 weeks resulted in a significant decrease in triglycerides, total protein, creatinine, creatine kinase, immunoglobulin profile (Ig A and Ig G) and T-cell sub-types (CD3(+), CD4(+), CD8(+) and CD56(+)). Whereas, it significantly increase serum level of AST, ALT, LDH and induced degenerative changes in pro-inflammatory cytokines (TNF-alpha and IL-1). Rats treated with TMC alone (400, 600 and 800 mg/kg BW) were comparable to the control regarding all the tested parameters. The combined treatment of CdCl(2) and TMC at the lowest dose (400 mg/kg BW) showed a significant improvement of all tested parameters. It could be concluded that TMC was effective to protect against Cd hazards at a dose as low as 400 mg/kg BW. These results supported our hypothesis that TMC tightly-bind and immobilized Cd resulted in reduction of metal bioavailability in the gastrointestinal tract.
Abbès
Samir
S
Laboratory of Environmental Immunology Microbiology and Cancerology, Faculty of Sciences Bizerte, Zarzouna, Tunisia. abb_samir@yahoo.fr
Salah-Abbès
Jalila Ben
JB
Nahdi
Kais
K
Ben Younes
Ridha
R
Hetta
Mona M
MM
El-Kady
Ahmed A
AA
Abdel-Wahhab
Mosaad A
MA
Oueslati
Ridha
R
D000327:Adsorption; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001546:Bentonite / Q000737:chemistry / Q000494:pharmacology*; D002104:Cadmium / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity*; D003402:Creatine Kinase / Q000097:blood; D003404:Creatinine / Q000097:blood; D006863:Hydrogen-Ion Concentration; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007375:Interleukin-1 / Q000097:blood / Q000276:immunology; D007668:Kidney / Q000378:metabolism; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D020011:Protective Agents / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013154:Spleen / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013950:Thymus Gland / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000276:immunology; D014416:Tunisia
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007375:Interleukin-1; D020011:Protective Agents; D014409:Tumor Necrosis Factor-alpha; D002104:Cadmium; D001546:Bentonite; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003402:Creatine Kinase